Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder

International Journal of Neuropsychopharmacology

Volumn 18, Issue 1, 2015, Pages

  Niciu, Mark J ^a   Luckenbaugh, David A ^a   Ionescu, Dawn F ^a   Richards, Erica M ^a   Vande Voort, Jennifer L ^a   Ballard, Elizabeth D ^a   Brutsche, Nancy E ^a   Furey, Maura L ^a   Zarate, Carlos A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Alcohol use disorder; Family history; Ketamine; Major depressive disorder; Riluzole

Indexed keywords

KETAMINE; PLACEBO; RILUZOLE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT;

ADULT; AGED; ALCOHOL USE DISORDER; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT RESISTANT DEPRESSION; ADOLESCENT; ALCOHOLISM; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FAMILY; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALCOHOL-RELATED DISORDERS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FAMILY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; KETAMINE; MIDDLE AGED; RILUZOLE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930628569     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyu039     Document Type: Article

References (46)

1. Aan Het Rot M, Zarate CA, Jr., Charney DS, Mathew SJ (2012) Ketamine for depression: where do we go from here? Biol Psychiatry 72:537-547.
2. Beck AT, Beamesderfer A (1974) Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatr 7:151-169.
3. Beck AT, Kovacs M, Weissman A (1979) Assessment of suicidal intention: the scale for suicide ideation. J Consult Clin Psychol 47:343-352.
4. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354.
5. Blier P, Zigman D, Blier J (2012) On the safety and benefits of repeated intravenous injections of ketamine for depression. Biol Psychiatry 72:e11-12.
6. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA, Jr. (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793-802.
7. Enoch MA (2013) Genetic influences on the development of alcoholism. Curr Psychiatry Rep 15:412.
8. Fink K, Gothert M (1996) Both ethanol and ifenprodil inhibit NMDA-evoked release of various neurotransmitters at different, yet proportional potency: potential relation to NMDA receptor subunit composition. Naunyn Schmiedebergs Arch Pharmacol 354:312-319.
9. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
10. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
11. Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, Moaddel R, Wainer I, Luckenbaugh DA, Manji HK, Zarate CA, Jr. (2012) Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebocontrolled study. Neuropsychopharmacology 37:1526-1533.
12. Kash TL, Matthews RT, Winder DG (2008) Alcohol inhibits NR2Bcontaining NMDA receptors in the ventral bed nucleus of the stria terminalis. Neuropsychopharmacology 33:1379-1390.
13. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095-3105.
14. Liebrenz M, Stohler R, Borgeat A (2009) Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World J Biol Psychiatry 10:640-643.
15. Lovinger DM (1995) Developmental decrease in ethanol inhibition of N-methyl-D-aspartate receptors in rat neocortical neurons: relation to the actions of ifenprodil. J Pharm Exp Ther 274:164-172.
16. Luckenbaugh DA, Ibrahim L, Brutsche N, Franco-Chaves J, Mathews D, Marquardt CA, Cassarly C, Zarate CA, Jr. (2012) Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. Bipolar Disord 14:880-887.
17. Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS (2010) Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychop 13:71-82.
18. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
19. Murrough JW, Perez AM, Mathew SJ, Charney DS (2011) A case of sustained remission following an acute course of ketamine in treatment-resistant depression. J Clin Psychiatry 72:414-415.
20. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ (2013) Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. Am J Psych 170:1134-1142.
21. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV (2013) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74:250-256.
22. Nery FG, Stanley JA, Chen HH, Hatch JP, Nicoletti MA, Monkul ES, Lafer B, Soares JC (2010) Bipolar disorder comorbid with alcoholism: a 1H magnetic resonance spectroscopy study. J Psychiatr Res 44:278-285.
23. Niciu MJ, Grunschel BD, Corlett PR, Pittenger C, Bloch MH (2013) Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessivecompulsive disorder and a history of major depressive disorder. J Psychopharmacol 27:651-654.
24. Niciu MJ, Ionescu DF, Mathews DC, Richards EM, Zarate CA (2013) Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder. CNS Spectr: 18:231-41.
25. Niciu MJ, Luckenbaugh DA, Ionescu DF, Guevara S, Machado- Vieira R, Richards EM, Brutsche NE, Nolan NM, Zarate CA, Jr. (2014) Clinical predictors of ketamine response in treatmentresistant major depression. J Clin Psychiatry 75:e417-423.
26. Niciu MJ, Mathews DC, Nugent AC, Ionescu DF, Furey ML, Richards EM, Machado-Vieira R, Zarate CA, Jr. (2014) Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants. Depress Anxiety 31:297-307.
27. Ormel J et al. (2008) Disability and treatment of specific mental and physical disorders across the world. Br J Psychiatry 192:368-375.
28. Permoda-Osip A, Skibinska M, Bartkowska-Sniatkowska A, Kliwicki S, Chlopocka-Wozniak M, Rybakowski JK (2014) Factors connected with efficacy of single ketamine infusion in bipolar depression. Psychiatr Pol 48:35-47.
29. Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA, Jr. (2009) Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 65:181-184.
30. Ressler KJ, Mercer KB, Bradley B, Jovanovic T, Mahan A, Kerley K, Norrholm SD, Kilaru V, Smith AK, Myers AJ, Ramirez M, Engel A, Hammack SE, Toufexis D, Braas KM, Binder EB, May V (2011) Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 470:492-497.
31. Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, Cook IA, Shelton RC, Lesser IM, Kornstein SG, Wisniewski SR (2011) Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psych 168:689-701.
32. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. Am J Psych 163:1905-1917.
33. Sackeim HA (2001) The definition and meaning of treatmentresistant depression. J Clin Psychiatry 62(Suppl 16):10-17.
34. Sanacora G, Kendell SF, Fenton L, Coric V, Krystal JH (2004) Riluzole augmentation for treatment-resistant depression. Am J Psych 161:2132.
35. Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH (2007) Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 61:822-825.
36. Schumann G et al. (2008) Systematic analysis of glutamatergic neurotransmission genes in alcohol dependence and adolescent risky drinking behavior. Arch Gen Psychiatry 65:826-838.
37. Szymkowicz SM, Finnegan N, Dale RM (2014) Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder. J Clin Psychopharmacol 34:285-286.
38. Thoma R, Mullins P, Ruhl D, Monnig M, Yeo RA, Caprihan A, Bogenschutz M, Lysne P, Tonigan S, Kalyanam R, Gasparovic C (2011) Perturbation of the glutamate-glutamine system in alcohol dependence and remission. Neuropsychopharmacology 36:1359-1365.
39. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ (2004) Global burden of depressive disorders in the year 2000. Br J Psychiatry 184:386-392.
40. Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G (2011) The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res 191:122-127.
41. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429-435.
42. Zarate CA, Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, Charney DS, Manji HK (2004) An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psych 161:171-174.
43. Zarate CA, Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864.
44. Zarate CA, Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA (2012) Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled addon trial. Biol Psychiatry 71:939-946.
45. Zarate CA, Jr, Mathews DC, Furey ML (2013) Human biomarkers of rapid antidepressant effects. Biol Psychiatry 73:1142-1155.
46. Zhou J, Nagarkatti P, Zhong Y, Ginsberg JP, Singh NP, Zhang J, Nagarkatti M (2014) Dysregulation in microRNA expression Is associated with alterations in immune functions in combat veterans with post-traumatic stress disorder. PLOS ONE 9:e94075.